
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is poised for success with its Breakthrough Therapy Designation, promising drug cadisegliatin, and potential success in reducing HbA1c and hypoglycemia in phase 3 trials. With the FDA prioritizing a cure or treatment for type 1 diabetes and a projected price target of $49, the stock has strong potential for growth. The company's focus on raising funds and pursuing other potential therapies, such as dorzagliatin, showcases its dedication to finding effective treatments for chronic diseases.
Bears say
vTv Therapeutics is a late-stage biopharmaceutical company with a primary focus on developing therapies for diabetes. However, the recent insulin withdrawal study raises concerns about potential side effects and indicates that the drug may not be as effective as initially anticipated. Additionally, the company has several non-core programs which may offer partnering optionality, but are not included in their current valuation. The company also faces some potential risks, including regulatory, commercial, and competitive risks. This negative outlook is further compounded by a lack of current financial success, as shown by the absence of significant revenues and earnings.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares